PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS BETWEEN THE ACE INHIBITOR CILAZAPRIL AND BETA-ADRENOCEPTOR ANTAGONIST PROPRANOLOL IN HEALTHY-SUBJECTS AND IN HYPERTENSIVE PATIENTS

被引：7
作者：
BELZ, GG
ESSIG, J
ERB, K
BREITHAUPT, K
HOOGKAMER, JFW
KNEER, J
KLEINBLOESEM, CH
机构：
[1] ZE KA PHA GMBH,ZENTRUM KARDIOVASC PHARMAKOL,WIESBADEN,FED REP GER
[2] HOFFMANN LA ROCHE LTD,DEPT CLIN RES,BASEL,SWITZERLAND
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1989年 / 27卷
关键词：
D O I：
10.1111/j.1365-2125.1989.tb03498.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S317 / S322
页数：6
相关论文
共 50 条
  • [41] Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects
    Damy, T
    Pousset, F
    Caplain, H
    Hulot, JS
    Lechat, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (01) : 113 - 123
  • [42] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN DWP16001, A NOVEL SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR, AND METFORMIN IN HEALTHY SUBJECTS.
    Chung, W.
    Lee, S.
    Na, J.
    Lee, S.
    Lee, S.
    Cho, J.
    Jang, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S39 - S40
  • [43] A COMPARISON OF CIRCADIAN-RHYTHMS OF BLOOD FIBRINOGEN AND BLOOD PLASMINOGEN BETWEEN HEALTHY-SUBJECTS, HYPERTENSIVE PATIENTS AND PATIENTS WITH VASCULAR-DISEASE
    PETRALITO, A
    CUFFARI, MA
    GIBIINO, S
    MANGIAFICO, RA
    MIANO, MF
    FIORE, CE
    HAEMOSTASIS, 1984, 14 (01) : 145 - 145
  • [44] LACK OF PHARMACOKINETIC INTERACTIONS BETWEEN THE NOVEL DPP-4 INHIBITOR LINAGLIPTIN (BI 1356) AND PIOGLITAZONE IN HEALTHY SUBJECTS
    Graefe-Mody, Ulrike
    Jungnik, Arvid
    Ring, Arne
    Dugi, Klaus A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09) : 1100 - 1100
  • [45] Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I-Comparison between Healthy Subjects and Patients with Hypertension
    Wensing, Georg
    Ochmann, Klaus
    Boettcher, Michael
    Schaefer, Anja
    Kuhlmann, Jochen
    BIOMARKER INSIGHTS, 2007, 2 : 81 - 93
  • [46] Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects.
    Fier, I. D.
    Brandquist, C. M.
    Abu-Rashid, M.
    Morclli, G.
    Joelum, E. O.
    Roach, J.
    Goblot, D.
    Riel, T.
    Bondrian, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09) : 1107 - 1107
  • [47] A COMPARISON OF CIRCADIAN-RHYTHMS OF SOME BLOOD-CLOTTING INDEXES BETWEEN HEALTHY-SUBJECTS, HYPERTENSIVE PATIENTS AND PATIENTS WITH VASCULAR-DISEASE
    PETRALITO, A
    CUFFARI, MA
    GIBIINO, S
    MANGIAFICO, RA
    MIANO, MF
    FIORE, CE
    CHRONOBIOLOGIA, 1983, 10 (04) : 404 - 405
  • [48] LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients
    Russell, Paul
    Stevenson, Chris
    Charron, Catherine
    Brindley, Charlie
    Singh, Dave
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [49] Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients
    Li, Jianke
    Klemm, Kirsti
    O'Farrell, A. Marie
    Guler, Hans-Peter
    Cherrington, Julie M.
    Schwartz, Sherwyn
    Boyea, Teresa
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (08) : 2003 - 2010
  • [50] PHARMACOKINETIC INTERACTIONS BETWEEN ACT-178882/MK-1597, A NEW RENIN INHIBITOR, AND ATORVASTATIN AND SIMVASTATIN IN HEALTHY MALE SUBJECTS.
    Nicolas, L. B.
    Treiber, A.
    Behm, M. O.
    Denney, W.
    Panebianco, D.
    Murphy, G.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S55 - S56
12345